For sponsors, the pilot represents an opportunity to explore a more collaborative and potentially faster path to IND clearance while also providing insight into how FDA may approach future regulatory modernization efforts.
Under the pilot, drug sponsors will partner with FDA-selected Qualified Research Institutions (QRIs) that possess significant scientific and regulatory expertise. These institutions will support preparation of IND applications and work closely with FDA during the pre-IND phase.
The most notable innovation is FDA’s willingness to review individual components of the IND package on a rolling basis before final submission of the complete IND, rather than waiting for the complete application to be finalized. The goal is to identify and resolve issues earlier, potentially reducing the likelihood of clinical holds during the standard 30-day IND review period.
FDA plans to select approximately 8 to 10 Sponsor-QRI pairs for the initial pilot cohort, with applications being accepted through October 30, 2026.
Traditionally, sponsors prepare their IND package independently, conduct pre-IND interactions as needed, and submit a complete application for FDA review. Regulatory questions are often identified during FDA review, which can result in information requests, delays, or clinical holds.
The Expedited IND Pilot introduces three important differences:
Importantly, FDA emphasizes that the Agency retains full regulatory authority and that participation in the pilot does not alter scientific, quality, nonclinical, or clinical requirements. Sponsors will still be expected to meet all applicable IND standards.
The pilot may offer several potential benefits for participating sponsors.
First, earlier identification of regulatory concerns could reduce development uncertainty and improve the quality of IND submissions. By addressing deficiencies before formal filing, sponsors may encounter fewer delays during IND review.
Second, the pilot reflects FDA’s increasing focus on accelerating development timelines, particularly for innovative therapies. While limited in scope, the initiative suggests that FDA is actively exploring more collaborative models for early-stage development.
Third, the pilot could provide valuable insight into future regulatory policy. FDA explicitly notes that the program may help inform future modernization efforts, including a potential accreditation framework for institutions that demonstrate strong scientific and regulatory capabilities.
Although the pilot is currently limited to a small number of participants, its broader significance may extend beyond the initial cohort. Sponsors should monitor:
The Expedited IND Pilot does not change FDA's scientific expectations, but it may change how sponsors engage with the Agency during early development. By promoting earlier interaction, rolling review of submission components, and collaboration with qualified research institutions, FDA is evaluating whether drug development can become more efficient without compromising regulatory rigor or patient safety.
For sponsors pursuing innovative therapies, the pilot represents an important signal that FDA is increasingly focused on reducing avoidable development delays and modernizing the path from discovery to first-in-human clinical trials.